The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an entirely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback